Development of cell-free transcription translation

Cell-free transcription-translation (TXTL) systems provide a robust platform for in vitro protein synthesis, transforming molecular biology, synthetic biology, and biotechnology by replicating natural protein synthesis outside of living cells with exceptional control and flexibility. Initially developed by Nirenberg and Matthaei in the 1960s using E. coli extracts, these systems have undergone substantial evolution, and now incorporate extracts from bacteria, yeast, and eukaryotes to construct comprehensive TXTL platforms. A cell-free extract comprises essential components, such as ribosomes, RNA polymerase, and tRNAs, enabling protein synthesis directed by DNA templates through transcription and translation. TXTL systems, offer distinct advantages, including rapid, efficient, and accurate synthesis of natural and non-natural proteins, enhanced chemical resistance, and streamlined labeling-often surpassing cell-based techniques. Their extensive application span synthetic biology and biopharmaceutical production. Despite this promise, challanges remain, including high cost, limited protein yield, lack of complex post-translational modifications, and extract instability. Future efforts will focus on overcoming these challenges by reducing costs, improving yields, expanding post-translational modification capabilities, enhancing stability, and developing continuous-flow systems. Ultimately, cell-free systems are poised to deepen our understanding of biological processes and drive the development of innovative biotechnological tools.